Cutler Group’s SELLAS Life Sciences SLS Stock Holding History

Cutler Group’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,500	Closed	-$2K	–	6305
2021 Q2	$2K	Sell	3,500 -6,200	-64%	-$60.5K	﹤0.01%	5074
2021 Q1	$2K	Buy	+9,700	New	+$79.4K	﹤0.01%	5006

Other funds holding SLS

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Equitable Holdings New York $15.5B AUM 19.09% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cutler Group's SLS Position: Q1 2023 in Review

Cutler Group sold out of SELLAS Life Sciences (SLS) in Q1 2023, closing a stake of 300 shares.

Cutler Group first reported a position in SLS in Q4 2016 and held it in 9 quarters. The position peaked at $147K in Q1 2021. 22 funds tracked by Wall St. Rank hold SLS as of Q1 2023.

Cutler Group reported no remaining SELLAS Life Sciences position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 300 SELLAS Life Sciences shares in Q1 2023.
Cutler Group first reported a position in SELLAS Life Sciences in Q4 2016 and held it in 9 quarters.
Cutler Group's SELLAS Life Sciences position peaked at $147K in Q1 2021.
22 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.